Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Accounts Payables (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Accounts Payables for 4 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables fell 33.18% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 33.18% year-over-year, with the annual reading at $1.1 million for FY2025, 33.18% down from the prior year.
  • Accounts Payables hit $1.1 million in Q4 2025 for Coya Therapeutics, down from $1.1 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.9 million in Q2 2024 to a low of $237579.0 in Q2 2023.
  • Historically, Accounts Payables has averaged $1.1 million across 4 years, with a median of $1.1 million in 2025.
  • Biggest five-year swings in Accounts Payables: skyrocketed 692.61% in 2024 and later plummeted 50.54% in 2025.
  • Year by year, Accounts Payables stood at $1.8 million in 2022, then plummeted by 36.34% to $1.2 million in 2023, then surged by 37.42% to $1.6 million in 2024, then tumbled by 33.18% to $1.1 million in 2025.
  • Business Quant data shows Accounts Payables for COYA at $1.1 million in Q4 2025, $1.1 million in Q3 2025, and $931344.0 in Q2 2025.